Vesigen Therapeutics
- Founded: 2019
- Location: Cambridge, MA
- Employee range: 11 - 50
- Clinical stage: RD
- Therapy area: Neurological diseases
- Drug types: NEU, OPH, IMM
- Lead product: Undisclosed
- Product link: https://www.vesigen.com/programs/
- Funding: $28.5M A Jul 2020
vesigen.com linkedin.com job board
Short description:
Fusogenic extracellular vesicle delivery technology
Drug notes:
Undisclosed programs RD ocular conditions, immune modulation
Long description:
Vesigen Therapeutics is a developing exosome-based therapies for the treatment of a variety of diseases. Exosomes are small vesicles that are released by cells and can deliver cargo to other cells. Vesigen’s exosome engineering platform allows the company to engineer exosomes to deliver specific therapeutic cargo, such as siRNA, mRNA, or proteins. Vesigen is developing exosome-based therapies for a variety of diseases, including cancer, neurodegenerative diseases, and inflammatory diseases. The company's lead product candidate, VSG-101, is an exosome-based therapy for the treatment of glioblastoma multiforme (GBM), a type of brain cancer.
Jobs:
© 2024 Work In Biotech LLC
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com